Navigation Links
AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Date:5/9/2013

tiation of human clinical trials, potentially addressing one of the major health risks facing both Russia and the rest of the world," remarked Andrey Boldyrev , General Director of CardioNova. "We are currently working with the CRO and the trial centers to distribute the approved protocol and making final preparations for the initiation of pre-screening and ultimately Phase 1 clinical trials in our Russian study centers."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain pharmacological compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova is developing, and seeks to eventually market AHRO-001, a product that has the potential to become a new standard of care for patients prone to atherosclerotic plaque accumulation.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Announces a New Board Member
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Releases 2011 Financial Results
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. AtheroNova Names New Director
8. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
9. AtheroNova Adds New Medical Advisor
10. Noted Atherosclerosis Researcher Joins AtheroNova Team
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... OncLive® is pleased to announce ... its Strategic Alliance Partnership program. , By ... Lineberger will have the opportunity to work with ... cutting-edge research initiatives, community-directed cancer prevention programs, and ... with OncLive to educate their peers by providing ...
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... regenerative medicine transplant therapies are biological, but not ... trials may seem to treat them as if ... as well as unsanctioned studies that constitute “stem ... transplantation as an approach to developing new regenerative ...
(Date:7/22/2014)... Web) July 21, 2014 (PRWEB) July 23, 2014 ... Biomaterials, at Rutgers University. , The goal ... ideas across the full spectrum of scientists working ... research and development topics that represent the most ... been programmed to:,     Provide faculty ...
(Date:7/22/2014)... 22, 2014 Even within a phylum so full of ... among other arthropods for its cruelty -- at least to ... the fly is a most predatory sort of parasite. It ... a smear of larvae, and leaves its wicked brood to ... , None of this would be possible without the fly,s ...
Breaking Biology Technology:OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... , NES-ZIONA, Israel, July 27, PROLOR ... that it has entered into an evaluation and option agreement with ... the Weizmann Institute of Science . Under ... from Yeda a license to develop a number of peptide drug ...
... , , , ... medicine is just in its adolescence today and I see our ... applications and global markets," stated Edward Pulwer, upon accepting the position ... Sechrist has been in business for over 30 ...
... , CALGARY, July 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... with the support of its contract manufacturer, SAFC Pharma(R), ... an initial 100-litre production run of REOLYSIN under cGMP ... of a series to be completed over the next ...
Cached Biology Technology:PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 2PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 3Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO 2Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2
(Date:7/23/2014)... especially the young, are highly sensitive to temperature and ... temperatures within a narrow range. Recently published research led ... School of Arts and Sciences, is the first to ... hive in process similar to how humans and other ... , "This study shows how workers effectively dissipate ...
(Date:7/23/2014)... fur seals, alongside decades of in-depth monitoring, has ... change on a population of top-predators. Published in ... that the seals have significantly altered in accordance ... with climate conditions. Despite a shift in the ... passing down through generations, leaving the population in ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
Breaking Biology News(10 mins):How honey bees stay cool 2Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... by Princeton University engineers could harness natural body ... pacemakers, mobile phones and other electronic devices. ... silicone rubber sheets, generates electricity when flexed and ... electrical energy. Shoes made of the material may ...
... by researchers with the U.S. Department of Energy,s Joint ... produce an advanced biofuel directly from biomass. Deploying the ... strain of Escherichia coli ( E. coli ) bacteria ... from fatty acids. "The fact that our microbes ...
... recent study at Oregon State University indicates that some past ... overestimated the number of live trees that burn up and ... a result. The research was done on the Metolius ... one-third or 100,000 acres of the area burned ...
Cached Biology News:Energy-harvesting rubber sheets could power pacemakers, mobile phones 2Microbes produce fuels directly from biomass 2Microbes produce fuels directly from biomass 3Effects of forest fire on carbon emissions, climate impacts often overestimated 2Effects of forest fire on carbon emissions, climate impacts often overestimated 3
...
... 4 deuterium atoms at the 3, 3', ... for use as an internal standard for ... LC-mass spectrometry. PGE1 is the theoretical cyclooxygenase ... is virtually undetectable in the plasma of ...
Direct ELISA Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: